Skip to main content
. 2021 Dec 10;12:805334. doi: 10.3389/fneur.2021.805334

Figure 1.

Figure 1

Change in monthly headache days after 3 months of erenumab treatment in patients with episodic migraine (EM) (dashed line) and chronic migraine (CM) (continuous line). ***p < 0.001 vs. baseline (Friedman's ANOVA, the post-hoc Dunn's test).